<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PIPERACILLIN/TAZOBACTAM </span><br/>(pi-per'a-cil-lin/taz-o-bac'tam)<br/><span class="topboxtradename">Zosyn<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span>; <span class="classification">antipseudomonal penicillin</span><br/><b>Prototype: </b>Piperacillin Sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 g, 3 g, 4 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Antibacterial combination product consisting of the semisynthetic piperacillin and the beta-lactamase inhibitor tazobactam.
         Tazobactam component does not decrease the activity of the piperacillin component against susceptible organisms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Tazobactam is an inhibitor of a wide variety of bacterial betalactamases. It has little antibacterial activity itself;
         however, in combination with piperacillin, it extends the spectrum of bacteria that are susceptible to piperacillin. Two-drug
         combination has antibiotic activity against an extremely broad spectrum of gram-positive, gram-negative, and anaerobic bacteria.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of moderate to severe appendicitis, uncomplicated and complicated skin and skin structure infections, endometritis,
         pelvic inflammatory disease, or nosocomial or community-acquired pneumonia caused by piperacillin-resistant, piperacillin/tazobactam-susceptible,
         beta-lactamase-producing bacteria.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to piperacillin, tazobactam, penicillins, cephalosporins, or beta-lactamase inhibitors such as clavulanic
         acid and sulbactam.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney failure; pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 3.375 g q6h, infused over 30 min, for 710 d<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i> 150300 mg piperacillin/kg/d divided q68h; <img src="../images/special/greaterorequal.gif"/><i>6 mo,</i> 240 mg piperacillin component/kg/d divided q8h<br/><br/><span class="indicationtitle">Nosocomial Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4.5 g q6h, infused over 30 min, for 710 d<br/><br/><span class="impairmenttitle">Renal Insufficiency</span><br/>Cl<sub>cr</sub> 2040 mL/min: 2.25 g q6h; <br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Verify correct IV concentration and rate of infusion for administration to infants or children with physician.
         		
      </p>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>For hemodialysis patients, the maximum dose is 2.25 g q8h; give one extra 0.75-g dose after each dialysis period.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Reconstitute powder with 5 mL of diluent (e.g., D5W, NS); shake well until dissolved. Further dilute to at least 50 mL of
                  selected diluent. Use single-dose vials immediately after reconstitution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give over at least 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminoglycosides,</b>
<b>Lactated Ringer's,</b>
<b>albumin,</b>
<b>blood products,</b>
<b>solutions containing sodium bicarbonate.</b>
<span class="incompattype"> Y-site:</span>
<b>Acyclovir,</b>
<b>aminoglycosides,</b>
<b>amiodarone, amphotericin B,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>azithromycin, chlorpromazine,</b>
<b>cisplatin,</b>
<b>dacarbazine,</b>
<b>daunorubicin,</b>
<b>doxorubicin,</b>
<b>doxycycline,</b>
<b>droperidol,</b>
<b>famotidine,</b>
<b>ganciclovir,</b>
<b>gemcitabine,</b>
<b>hydroxyzine,</b>
<b>idarubicin,</b>
<b>minocycline,</b>
<b>mitomycin,</b>
<b>mitoxantrone,</b>
<b>nalbuphine,</b>
<b>prochlorperazine,</b>
<b>promethazine,</b>
<b>vancomycin.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, insomnia, fever. <span class="typehead">GI:</span> Diarrhea, constipation, nausea, vomiting, dyspepsia, <span class="speceff-life">pseudomembranous colitis</span>. <span class="typehead">Skin:</span> Rash, pruritus, hypersensitivity reactions. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase risk of bleeding with <span class="classification">anticoagulants</span>; <b>probenecid</b> decreases elimination of piperacillin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Distributes into many tissues, including lung, blister fluid, and bile; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Piperacillin and tazobactam are excreted in urine. <span class="typehead">Half-Life:</span> 0.71.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Obtain history of hypersensitivity to penicillins, cephalosporins, or other drugs prior to administration.</li>
<li>Lab tests: C&amp;S prior to first dose of the drug; start drug pending results. Monitor hematologic status with prolonged therapy
            (Hct and Hgb, CBC with differential and platelet count).
         </li>
<li>Monitor patient carefully during the first 30 min after initiation of the infusion for signs of hypersensitivity (see Appendix
            F).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report rash, itching, or other signs of hypersensitivity immediately.</li>
<li>Report loose stools or diarrhea as these may indicate pseudomembranous colitis.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>